??-Secretase Inhibitors for Alzheimer??s Disease
Authors:
- Donna M. BartenDBDonna M. Barten
- Jere E MeredithJMJere E Meredith
- John G. HoustonJHJohn G. Houston
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs in R&D
- Vol. 7 (2) , 87-97
Abstract
The amyloid hypothesis, which states that β-amyloid (Aβ) aggregates cause the onset and progression of Alzheimer’s disease (AD), is a leading proposal to explain AD aetiology. Based on this hypothesis, compounds that inhibit γ-secretase, one of the enzymes responsible for forming Aβ, are potential therapeutics for AD. Preclinical studies clearly establish that γ-secretase inhibitors can reduce brain Aβ in rodent models. The initial investigation of the effects of a γ-secretase inhibitor on Aβ-induced cognitive deficits in transgenic mice showed that modest Aβ reductions (15–30%) are sufficient to reverse Aβ-induced cognitive deficits in Tg2576 mice. Extending these studies to other γ-secretase inhibitors and other models with Aβ-induced cognitive deficits will be important. Unfortunately, γ-secretase inhibitors also cause abnormalities in the gastrointestinal tract, thymus and spleen in rodents. These changes likely result from inhibition of Notch cleavage, a transmembrane receptor involved in regulating cell-fate decisions. Two recent studies in rodents suggest that Aβ reduction using γ-secretase inhibitors can be partially separated from Notch inhibition. Given the uncertain Aβ reduction target and the potential for mechanism-based toxicity, biomarkers for efficacy and toxicity would be helpful in clinical trials. The first report of γ-secretase inhibitors in clinical trials was recently published. In this study, LY-450139 reduced plasma Aβ, but not cerebrospinal fluid Aβ. Taken together, the results of studies to date suggest that γ-secretase inhibitors have the potential to address a large unmet medical need if the technical challenges can be overcome.Keywords
This publication has 88 references indexed in Scilit:
- Behavioral phenotypes of amyloid‐based genetically modified mouse models of Alzheimer's diseaseGenes, Brain and Behavior, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Deciphering the Molecular Basis of Memory Failure in Alzheimer's DiseaseNeuron, 2004
- Intramembrane Proteolysis: Theme and VariationsScience, 2004
- Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical TrialsArchives of Neurology, 2004
- Distinct presenilin‐dependent and presenilin‐independent γ‐secretases are responsible for total cellular Aβ productionJournal of Neuroscience Research, 2003
- Presenilin-1 and Presenilin-2 Exhibit Distinct yet Overlapping γ-Secretase ActivitiesJournal of Biological Chemistry, 2003
- PROTOFIBRILS, PORES, FIBRILS, AND NEURODEGENERATION: Separating the Responsible Protein Aggregates from The Innocent BystandersAnnual Review of Neuroscience, 2003
- Alzheimer's Disease: Genes, Proteins, and TherapyPhysiological Reviews, 2001
- Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiencyProceedings of the National Academy of Sciences, 1999